Cizzle Biotechnology Holdings PLC (LSE:CIZ) has reported major progress in its U.S. commercialization strategy. Its North American partner, Cizzle Bio Inc., has signed an agreement with a leading national clinical diagnostics group to introduce the CIZ1B biomarker test across the United States. The initiative is designed to strengthen Cizzle’s market footprint in North America and broaden access to early-stage lung cancer screening.
As part of the arrangement, Cizzle and Cizzle Bio have also agreed to a revised royalty payment structure. Under the new schedule, all outstanding advance royalties will be fully paid by the end of 2026—earlier than originally planned. The adjustment highlights both partners’ commitment to accelerating deployment of the test while improving Cizzle’s financial outlook through faster revenue recognition.
About Cizzle Biotechnology Holdings PLC
Based in the UK, Cizzle Biotechnology is dedicated to advancing diagnostics for early cancer detection. Its flagship product, the CIZ1B biomarker, has been developed into a cost-effective, non-invasive blood test aimed at detecting lung cancer at earlier, more treatable stages. The company operates under a licensing model that generates royalties from commercialization agreements and works alongside leading cancer research institutions. Cizzle was admitted to the London Stock Exchange in May 2021.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply